Biomea Fusion BMEA 深 沪
等待开盘 12-20 09:30:00 美东时间
1.335
-0.015
-1.11%
华盛通- 最 高1.38
- 今 开1.38
- 成交量 35.64万股
- 最 低 1.305
- 昨 收 1.35
- 总市值 7944.38万
- 52周最高 4.59
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.8719
- 委 比 77.17%
- 总股本 5950.85万
- 历史最高 43.69
- 量 比 1.19
- 振 幅 5.56%
- 历史最低 0.8719
- 每 手 1
- 风险率 0.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
Biomea Fusion, a clinical-stage biopharmaceutical company, announced that its Interim CEO, Mick Hitchcock, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company will also host one-on-one meetings during the event. A live audio webcast of the presentation and its replay will be available through Biomea’s website. Biomea focuses on developing therapies for diabetes and obesity, targeting metabolic disord...
12-17 12:00
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
Dr. Ralph DeFronzo, a leading expert, highlighted the potential of icovamenib, a menin inhibitor, in treating diabetes during the WCIRDC 2025 conference. He discussed its mechanism of action, clinical results from the COVALENT-111 study, and its combination with GLP-1 therapies. Icovamenib aims to restore beta cell function, addressing a critical need in insulin-deficient diabetes. Biomea Fusion emphasizes its commitment to developing this innova...
12-09 23:35
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Biomea Fusion, a clinical-stage diabetes and obesity company, announced its selection to present long-term follow-up data on icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease (WCIRDC) in Los Angeles. The presentation, focusing on the Week 52 data, highlights icovamenib's potential as a paradigm shift in treating type 2 diabetes, particularly for insulin-deficient patients. Icovamenib, an oral menin ...
12-01 21:10
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion, a clinical-stage company developing diabetes and obesity treatments, granted a new employee 7,500 non-qualified stock options under its 2023 Inducement Equity Plan, approved on November 17, 2023. The options, which vest quarterly over four years, align with Nasdaq Listing Rule 5635(c)(4) to induce employment.
12-01 21:05
Biomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion, a clinical-stage biopharmaceutical company focused on diabetes and obesity, will participate in two investor conferences: the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York, and the Evercore 8th Annual Healthcare Conference on December 3, 2025, in Coral Gables, FL. The company will host fireside chats and one-on-one meetings at both events. Audio webcasts will be available on Biomea’s website, with...
11-24 12:00
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
D. Boral Capital Maintains Buy on Biomea Fusion, Lowers Price Target to $12
D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers the price target from $16 to $12.
11-05 21:39
Biomea Fusion Q3 EPS $(0.27) Misses $(0.26) Estimate
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.26) by 2.27 percent. This is a 70.33 percent increase over losses of $(0.91) per share from
11-05 05:46
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
Biomea Fusion reported third-quarter financial results and business updates, highlighting advancements in its icovamenib and BMF-650 programs for diabetes and obesity. Icovamenib demonstrated durable 52-week Phase II data, with significant HbA1c reductions and favorable safety profiles. BMF-650 initiated its Phase I trial, targeting obesity. The company raised $68 million, extending its cash runway into Q1 2027. Operating expenses decreased by ov...
11-04 21:05
